Ribosomal Protein L22L1 CRISPR/Cas9 KO Plasmid (h): sc-402323
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Ribosomal Protein L22L1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Ribosomal Protein L22L1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ribosomal Protein L22L1 CRISPR/Cas9 KO Plasmid (h) | sc-402323 | 20 µg | $397.00 |
Overview
RPL22L1 encodes Ribosomal Protein L22L1, a component of the 60S large ribosomal subunit that supports ribosome biogenesis and efficient mRNA translation. Through its contribution to translational control, RPL22L1 can influence proteostasis, cell-cycle progression, and stress-adaptive programs that depend on selective mRNA recruitment and ribosomal function. Altered regulation of ribosomal proteins and ribosome assembly factors is frequently linked to dysregulated growth programs and genome maintenance pathways, making RPL22L1 relevant for studies of ribosome-associated vulnerabilities in proliferative states. This gene is therefore of interest for mechanistic work connecting translational capacity to cellular homeostasis and disease-associated phenotypes.
Ribosomal Protein L22L1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the RPL22L1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the RPL22L1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the RPL22L1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Ribosomal Protein L22L1 protein expression.
This CRISPR knockout system enables efficient generation of RPL22L1-deficient cell models for investigation of Ribosomal Protein L22L1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting RPL22L1 exon(s) critical for Ribosomal Protein L22L1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple RPL22L1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Ribosomal Protein L22L1 CRISPR/Cas9 KO Plasmid (h) and Ribosomal Protein L22L1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the RPL22L1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Ribosomal Protein L22L1 HDR Plasmid (h) and Ribosomal Protein L22L1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by RPL22L1 homology arms to support homology-directed repair at defined RPL22L1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.